Jim Cramer Cautions Investors on Nuvation Bio as Wall Street Targets 113% Upside
CNBC commentator Jim Cramer labeled biopharmaceutical firm Nuvation Bio a speculative bet during a recent Mad Money episode, contrasting with Wall Street analysts who see substantial upside following key clinical and commercial milestones.
